In spring 2026, China’s biopharmaceutical sector saw a surge in “going global via Hong Kong”, with InvestHK bringing in 17 biotech companies driving over HK$1.3 billion in investment, while the sixth batch of 22 strategic enterprises included Hengrui, Pfizer, and Amgen. Three models emerged: policy-driven, capacity-building, and platform-enabled. Hong Kong’s edge lies in a triple convergence: PIC/S mutual recognition, 30 years of Hospital Authority real-world data, and the HK$10 billion I&T Fund plus Hetao synergy. The industry is now transitioning from using Hong Kong as a launchpad to deepening its global presence.
Full article published in Hong Kong Economic Times, written by Stella Law of CHFT Advisory and Appraisal.